NYNurdan Yıldız

Nurdan Yıldız

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Nurdan Yıldız has a total of 130 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Clinical course of proteinuria due to cubilin variants: a large multicenter pediatric cohort

    by Neslihan Cicek, Ceren Alavanda, Ayse Seda Pınarbası, Aylin Inal, Bahriye Atmıs, Secil Kezer, Mehtap Akbalik Kara, Okan Akaci, Serim Pul, Sevcan Hatipoglu, et al.

    Introduction: We aimed to evaluate the clinical and genetic characteristics and clinical course of children with persistent proteinuria associated with CUBN variants. Methods: Forty-eight children with CUBN variants from 15 pediatric nephrology centers were included. Patients’ characteristics, serum creatinine, albumin, hemoglobin, vitamin B12 levels, urinalysis, spot urine protein/creatinine (uPCR), microalbumin/creatinine (uACR), beta-2 microglobulin/creatinine (uBMCR) ratios, estimated glomerular filtration rates (eGFRs), treatments, kidney biopsies, and genetic findings were evaluated. Results: All patients had normal serum albumin and creatinine and preserved eGFR. There was no significant change in eGFR between the first and last visits ( p = 0.15), whereas uPCR was lower at the last visit ( p = 0.001). Kidney biopsy was performed in 13 (27%); light microscopy was normal in all except one patient with focal segmental glomerulosclerosis (FSGS). Thirty-five patients (72.9%) had ACEi/ARB therapy, which was discontinued in 21 patients without subsequent worsening of proteinuria. Overall, 26 distinct CUBN variants were identified, predominantly in the C-terminal region. The most frequent variant was c.10102A > G (p.Met3368Val). Variant types included 15 (57.7%) missense, 7 (27%) nonsense, 3 (11.5%) splicing, and 1 (3.8%) frameshift variants. Conclusions: In this multicenter, large pediatric cohort, proteinuria associated with CUBN variants generally followed a benign course over short to mid-term follow-up even without sustained ACEi/ARB therapy. Embedding targeted CUBN testing into the evaluation of children with asymptomatic proteinuria and normal kidney function may reduce unnecessary kidney biopsies and prolonged medication, while improving family counseling. We outline a stepwise care pathway → early genetic screening → conservative monitoring with periodic eGFR and proteinuria assessment → consideration of ACEi/ARB discontinuation and recommend prospective validation and cost-effectiveness studies.


  • Predictors of kidney survival in children with autosomal recessive polycystic kidney disease

    by Neslihan Çiçek, İbRahim Gökçe, Ceren Alavanda, Serçin Güven, Mehtap Kaya, Serim Pul, Özde Nisa Türkkan, Nurdan Yıldız, Pınar Ata

    Background The phenotype of autosomal recessive polycystic kidney disease (ARPKD) can be quite variable: some patients progress to end-stage kidney disease (ESKD) in infancy, while others may not require kidney replacement therapy (KRT) until later childhood or adolescence. This study aimed to evaluate clinical, biochemical, imaging, and genetic findings that may influence kidney prognosis in pediatric patients with ARPKD. Methods The patients diagnosed before birth or in the first month were classified as perinatal presenters and later than 1 month as non-perinatal presenters. Additionally, groups were formed based on estimated glomerular filtration rate (eGFR) at the last visit and variant types. Results Seventeen patients (8 male, 9 female) were enrolled in the study. Kidney survival rates at 5 years was 71.4% in the perinatal group, whereas it was 100% in the non-perinatal group. The early height-adjusted kidney dimension (haKD) was positively correlated with perinatal presentation and antenatal diagnosis. At the last follow-up, the mean eGFR was significantly lower in the truncating group with four patients (23.5%) progressing to stage-5 chronic kidney disease (CKD). Conclusions The kidney survival rate is lower in patients with early presentation. Initial low eGFR and severe variants are important predictors of kidney survival. Additionally, early high haKD may be associated with poor kidney outcome. Further studies with larger patient populations and long-term follow-up are necessary to better understand the prognosis of pediatric patients with ARPKD.

  • Successful Use of Haploidentical HSCT in a Child With Schimke Immuno‐Osseous Dysplasia Who Developed PTLD After Kidney Transplantation

    by Cemile Pehlivanoğlu, Fatih Erbey, Özlem Ünlügedik, Başak Akyollu, Ebru Yılmaz, Musa Karakükçü, Banu Oflaz Sözmen, Sevgi Bilgiç Eltan, Nurdan Yıldız, Burak Koçak, et al.

    Background: Schimke Immuno‐Osseous Dysplasia Is a Rare Autosomal Recessive Multisystem Disorder Caused by Biallelic Pathogenic Variants in the SMARCAL1 Gene, Which Encodes a DNA Annealing Helicase Essential for Replication Fork Stability and Genomic Maintenance. Loss of SMARCAL1 Function Leads to Genomic Instability, Resulting in a Characteristic Clinical Triad of Disproportionate Short Stature, Steroid‐Resistant Nephrotic Syndrome and Immunodeficiency. Kidney Transplantation Is the Standard Treatment for End‐Stage Renal Disease in Schimke Immuno‐Osseous Dysplasia. However, the Underlying Genomic Fragility and Immunodeficiency Heighten the Risk of Post‐Transplant Complications, Particularly Epstein–Barr Virus‐Associated Post‐Transplant Lymphoproliferative Disorder. Method: We Report the Case of a 7‐Year‐Old Girl With Genetically Confirmed Schimke Immuno‐Osseous Dysplasia Who Developed Epstein–Barr Virus‐Positive Diffuse Large B‐Cell Lymphoma Eight Months Following Maternal Kidney Transplantation, Despite Reduced‐Intensity Immunosuppression. Rituximab Therapy Resulted in Complete Remission, but Required the Withdrawal of all Immunosuppressive Agents, Thereby Posing a Risk of Kidney Graft Loss. Result: In the Context of Primary Immunodeficiency and the Development of Post‐Transplant Lymphoproliferative Disorder in Such a Setting, the Patient Subsequently Underwent Haploidentical Hematopoietic Stem Cell Transplantation From the Mother, Using an αβ T‐Cell‐Depleted Graft and a Nephrotoxicity‐Sparing Conditioning Regimen. Full Donor Chimerism Was Achieved by Day 28. Immune Reconstitution Occurred Within One Year. At 27 Months After Hematopoietic Stem Cell Transplantation She Remains in Remission With Preserved Kidney Function and no Ongoing Immunosuppression. Conclusion: This Case Highlights the Feasibility of Haploidentical Hematopoietic Stem Cell Transplantation as a Curative Salvage Strategy for Immunosuppression‐Free Survival After Kidney Transplantation in Patients With Schimke Immuno‐Osseous Dysplasia.


  • Open Access

    Humoral and cellular immune response to SARS-CoV-2 mRNA BNT162b2 vaccine in pediatric kidney transplant recipients compared with dialysis patients and healthy children

    by Ruveyda Gulmez, Dogukan Ozbey, Ayse Agbas, Bagdagul Aksu, Nurdan Yildiz, Diana Uckardes, Seha Saygili, Esra Karabag Yilmaz, Zeynep Yuruk Yildirim, Mehmet Tasdemir, et al.

    Background Compared with the general population, the immune response to COVID-19 mRNA vaccines is lower in adult kidney transplant recipients (KTRs). However, data is limited for pediatric KTRs. In this study, we aimed to assess humoral and cellular immune responses to the COVID-19 mRNA vaccine in pediatric KTRs. Methods This multicenter, prospective, case–control study included 63 KTRs (37 male, aged 12–21 years), 19 dialysis patients, and 19 controls. Humoral (anti-SARS-CoV2 IgG, neutralizing Ab (nAb)) and cellular (interferon-gamma release assay (IGRA)) immune responses were assessed at least one month after two doses of BNT162b2 mRNA vaccine. Results Among COVID-19 naïve KTRs (n = 46), 76.1% tested positive for anti-SARS-CoV-2 IgG, 54.3% for nAb, and 63% for IGRA. Serum levels of anti-SARS-CoV-2 IgG and nAb activity were significantly lower in KTRs compared to dialysis and control groups (p < 0.05 for all). Seropositivity in KTRs was independently associated with shorter transplant duration (p = 0.005), and higher eGFR (p = 0.007). IGRA titer was significantly lower than dialysis patients (p = 0.009). Twenty (43.4%) KTRs were positive for all immune parameters. Only four of 11 seronegative KTRs were IGRA-positive. COVID-19 recovered KTRs had significantly higher anti-SARS-CoV-2 IgG and nAb activity levels than COVID-19 naïve KTRs (p = 0.018 and p = 0.007, respectively). Conclusions The humoral and cellular immune responses to SARS-CoV-2 mRNA BNT162b2 vaccine are lower in pediatric KTRs compared to dialysis patients. Further prospective studies are required to demonstrate the clinical efficacy of the mRNA vaccine in KTRs. This prospective study was registered in ClinicalTrials.gov (NCT05465863, registered retrospectively at 20.07.2022). Graphical abstract A higher resolution version of the Graphical abstract is available as Supplementary information.


  • Clinical and genetic characterization of children with cubilin variants

    by Neslihan Cicek, Harika Alpay, Sercin Guven, Ceren Alavanda, Özde Nisa Türkkan, Serim Pul, Ece Demirci, Nurdan Yıldız, Pınar Ata, Ibrahim Gokce

    Background Cubilin is one of the receptor proteins responsible for reabsorption of albumin in proximal tubules and is encoded by the CUBN gene. We aimed to evaluate clinical and genetic characterization of six patients with proteinuria who had CUBN mutations. Methods Patients’ characteristics, serum creatinine, albumin, vitamin B12 levels, urine analysis, spot urine protein/creatinine, microalbumin/creatinine, beta-2 microglobulin/creatinine ratios, estimated glomerular filtration rates (eGFR), treatments, kidney biopsies, and genetic analyses were evaluated. Results Six patients (2 female, 4 male) with an incidental finding of proteinuria were evaluated. Mean admission age and follow-up time were 7.3 ± 2.9 and 6.5 ± 5.6 years, respectively. Serum albumin, creatinine, and eGFR were normal; urine analysis revealed no hematuria, and C3, C4, ANA, and anti-DNA were negative; kidney ultrasonography was normal for all patients. Urine protein/creatinine was 0.9 ± 0.3 mg/mg, and microalbumin was high in all patients. Serum vitamin B12 was low in two patients and normal in four. Kidney biopsy was performed in four patients, three demonstrated normal light microscopy, and there was one focal segmental glomerulosclerosis (FSGS). Genetic tests revealed four homozygous and two compound heterozygous mutations in the C-terminal part of cubilin. All patients had normal eGFR and still had non-nephrotic range proteinuria at last visit. Conclusions CUBN gene mutations should be considered in patients with isolated non-nephrotic range proteinuria and normal kidney function. Diagnosing these patients, who are thought to have a better prognosis, is important in terms of avoiding unnecessary treatment and predicting prognosis. CUBN gene mutations may also present as FSGS which extends the spectrum of renal manifestation of these patients. Graphical abstract A higher resolution version of the Graphical abstract is available as Supplementary information


  • Open Access

    Molecular Aspects of Distal Kidney Tubular Acidosis in Children, Its Long-Term Outcome, and Relationship with Hyperammonemia

    by Serçin Güven, İbRahim Gökçe, Ceren Alavanda, Burcu Öztürk Hişmi, Neslihan Çiçek, Ece Bodur Demirci, Mehtap Sak, Nurdan Yıldız, Pınar Ata, Harika Alpay

    Objective: We aimed to present the characteristics, genetic analysis results, long-term progno- sis of our patients with distal kidney tubular acidosis, and the relationship between hyperam- monemia and distal kidney tubular acidosis. Materials and Methods: Biochemical, clinical, and imaging findings were collected at presen- tation and the last clinic visit, and results of the genetic analysis were recorded. Results: Our study included 9 patients (3 female, 33%). The median age at diagnosis was 3 months, and the median follow-up period was 111 months. Height standard deviation scores were less than −2 in 4 (44%) patients at presentation and in 3 (33%) at the last clinic visit. The median estimated glomerular filtration rate was 98 mL/min/1.73 m2 at presentation and 126 mL/min/1.73 m2 at the last clinic visit. We have found 8 different types of mutations of 2 genes, including 6 in the ATP6V0A4 gene, 2 in the SLCA4A1 gene, and 2 of them were novel. At the time of presentation, nephrocalcinosis and hypercalciuria were present in all our patients, but at the last visit, only 1 patient had hypercalciuria. Sensorineural hearing loss was found in 4 of our patients with a mutation in the ATP6V0A4 gene. Serum ammonia levels were found to be high in 3 patients with mutations in the ATP6V0A4 gene. Conclusion: Adequate metabolic control is essential for optimal growth and preserved kidney function in distal kidney tubular acidosis patients. Distal kidney tubular acidosis may be associ- ated with hyperammonemia. We recommend keeping potassium levels at high-normal levels to reduce ammonia levels, especially in the absence of acidosis. Cite this article as: Güven S, Gökçe İ, Alavanda C, et al. Molecular aspects of distal kidney tubular acidosis in children, its long-term outcome, and relationship with hyperammonemia. Turk Arch Pediatr. 2022;57(4):432-440.


  • Open Access

    Clinical Course of Idiopathic Nephrotic Syndrome in Children: predictors of steroid resistance

    by Nurdan Yildiz, Neslihan Cicek, Sercin Guven, Ibrahim Gokce, Harika Alpay

    Background: Nephrotic Syndrome (NS) is one of the most common renal diseases in children. Clinical response to corticosteroids is an important prognostic factor for long-term renal outcome. We aimed to evaluate the clinical parameters, histopathological findings and complications of NS patients and factors predicting steroid resistance in a single tertiary center. Methods: A hundred and sixty two children (57 girls, 105 boys) with NS followed between 1998 and 2018 in Department of Pediatric Nephrology were analyzed in a retrospective cohort. Secondary causes and infantile NS cases were excluded. Results: The median (IQR; range) age of the children at presentation and follow up time were 4.9(5.7; 0.1-16.8) and 5.5(5.4; 0.1-20.3) years, respectively. A hundred and thirty four (82.7%) patients were steroid-sensitive nephrotic syndrome (SSNS) and 28(17.3%) were steroid-resistant nephrotic syndrome (SRNS). Age at the first presentation was lower in SSNS group (p=0.002). Hypertension, macroscopic and microscopic hematuria were higher in SRNS group (pConclusion:The late onset is still an important sign for SRNS. Microscopic and macroscopic hematuria and hypertension may also give a hint for potential steroid resistance. We emphasize that FSGS is a biopsy finding that may reveal to different diagnosis in SRNS.


  • Open Access

    COVID-19 in pediatric nephrology centers in Turkey

    by Emre Leventoğlu, Yeşim Özdemir Atikel, Hülya Nalçacıoğlu, İsmail Dursun, Hasan Dursun, Zeynep Nagehan Yürük Yıldırım, Nurdan Yıldız, Gülşah Kaya Aksoy, Mehmet Taşdemir, Mehtap Çelakıl, et al.

    Background/aim: There is limited data on COVID-19 disease in children with kidney disease. We aimed to investigate the characteristics and prognosis of COVID-19 in pediatric nephrology patients in Turkey. Materials and methods: This was a national, multicenter, retrospective cohort study based on an online survey evaluating the data between 11th March 2020 and 11th March 2021 as an initial step of a detailed pediatric nephrology COVID-19 registry. Results: Two hundred and three patients (89 girls and 114 boys) were diagnosed with COVID-19. One-third of these patients (36.9%) were between 10-15 years old. Half of the patients were on kidney replacement therapy: kidney transplant (KTx) recipients (n = 56, 27.5%), patients receiving chronic hemodialysis (n = 33, 16.3%) and those on peritoneal dialysis (PD) (n = 18, 8.9%). Fifty-four (26.6%) children were asymptomatic. Eighty-two (40.3%) patients were hospitalized and 23 (28%) needed intensive care unit admission. Fiftyfive percent of the patients were not treated, while the remaining was given favipiravir (20.7%), steroid (16.3%), and hydroxychloroquine (11.3%). Acute kidney injury developed in 19.5% of hospitalized patients. Five (2.4%) had MIS-C. Eighty-three percent of the patients were discharged without any apparent sequelae, while 7 (3.4%) died. One hundred and eight health care staff were infected during the study period. Conclusion: COVID-19 was most commonly seen in patients who underwent KTx and received HD. The combined immunosuppressive therapy and frequent exposure to the hospital setting may increase these patients' susceptibility. Staff infections before vaccination era were alarming, various precautions should be taken for infection control, particularly optimal vaccination coverage.


  • Open Access

    PROGRESS STUDY: Progression of chronic kidney disease in children and heat shock proteins

    by Zeynep Nagehan Yuruk Yildirim, Sebahat Usta Akgul, Harika Alpay, Bagdagul Aksu, Fatma Savran Oguz, Aysel Kiyak, Nurver Akinci, Sevgi Yavuz, Gul Ozcelik, Asuman Gedikbasi, et al.


  • Open Access

    Rituximab treatment for difficult-to-treat nephrotic syndrome in children: a multicenter, retrospective study

    by Mehmet Taşdemir, Nur Canpolat, Nurdan Yildiz, Gül Özçelik, Meryem Benzer, Seha Kamil Saygili, Emine Neşe ÖZKAYIN, Özde Nisa Türkkan, Ayşe BALAT, Cengiz Candan, et al.

    Background/aim: This study aimed to evaluate the efficacy of rituximab in children with difficult-to-treat nephrotic syndrome, considering the type of disease (steroid-sensitive or -resistant) and the dosing regimen. Materials and methods: This multicenter retrospective study enrolled children with difficult-to-treat nephrotic syndrome on rituximab treatment from 13 centers. The patients were classified based on low (single dose of 375 mg/m(2)) or high (2-4 doses of 375 mg/m(2)) initial dose of rituximab and the steroid response. Clinical outcomes were compared. Results: Data from 42 children [20 steroid-sensitive (frequent relapsing / steroid-dependent) and 22 steroid-resistant nephrotic syndrome, aged 1.9-17.3 years] were analyzed. Eleven patients with steroid-sensitive nephrotic syndrome (55%) had a relapse following initial rituximab therapy, with the mean time to first relapse of 8.4 +/- 5.2 months. Complete remission was achieved in 41% and 36% of steroid-resistant patients, with the median remission time of 3.65 months. At Year 2, eight patients in steroid-sensitive group (40%) and four in steroid-resistant group (18%) were drug-free. Total cumulative doses of rituximab were higher in steroid-resistant group (p = 001). Relapse rates and time to first relapse in steroid-sensitive group or remission rates in steroid-resistant group did not differ between the low and high initial dose groups. Conclusion: The current study reveals that rituximab therapy may provide a lower relapse rate and prolonged relapse-free survival in the steroid-sensitive group, increased remission rates in the steroid-resistant group, and a significant number of drug-free patients in both groups. The optimal regimen for initial treatment and maintenance needs to be determined.